We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,188

Member States cannot impose uniform retail prices for prescription-only medicinal products, highest EU Court says
  • White & Case LLP
  • European Union, Germany
  • October 21 2016

EU law precludes national legislation setting fixed retail prices for prescription medicinal products, as it unreasonably restricts imports On 19


Royalties for revoked patents do not necessarily breach EU competition rules
  • Penningtons Manches LLP
  • European Union, Germany, USA
  • October 25 2016

It is hard to imagine that when Genentech signed a licence agreement in 1992 with Sanofi's predecessor, it could have foreseen the litigation storm


German Federal Patent Court Grants Compulsory License on HIV Drug Patent
  • Mayer Brown LLP
  • Germany
  • November 9 2016

On 31 August 2016, the German Federal Patent Court issued a compulsory license under a patent that protects an HIV drug to affiliates of Merck & Co


Pricing for new innovative drugs public payers attempt new approach
  • McDermott Will & Emery
  • Germany
  • June 18 2014

In 2011 an additional benefit assessment for innovative drugs and consecutive price negotiations known as the AMNOG procedure entered into force


Federal Court of Justice: extended advertising options for the pharmaceutical industry
  • Baker McKenzie
  • Germany
  • March 26 2013

In its judgment dated 2 February 2013 (I ZR 6211) the German Federal Court of Justice (BundesgerichtshofBGH) extended the advertising options for


Decision on stricter anti-corruption rules in healthcare sector deferred
  • CMS
  • Germany
  • October 28 2013

Tightening anti-corruption rules in the healthcare sector has been on the government's agenda for some time. The debate about the scope and


Bolar exemption - C-66113 - Astellas Pharma referral to the CJ
  • D Young & Co
  • European Union, Germany
  • April 7 2014

The Dusseldorf Court of Appeal has referred questions to the Court of Justice of the European Union (CJ) concerning the applicability of the


El Tribunal de Justicia y la fijación unitaria de precios de medicamentos
  • Cuatrecasas Gonçalves Pereira
  • Germany
  • November 4 2016

La Sala Primera del Tribunal de Justicia ha analizado en su reciente Sentencia la normativa alemana sobre la fijación de precios uniformes para la


German Federal Court: Permission granted - HIVAIDS drug distribution continued
  • Hogan Lovells
  • European Union, Germany
  • July 17 2017

The X. Civil Senate of the German Federal Court of Justice has granted a motion by three companies of the Merck Sharp & Dohme group (Merck) for a


Johnson & JohnsonNovartis another challenge to pay for delay: is this ever permissible?
  • Bryan Cave LLP
  • European Union, France, Germany, Italy, United Kingdom
  • January 14 2014

In the latest challenge to so-called “pay for delay” or “reverse payment” agreements, on 10 December 2013, the European Commission fined the